BiotechTube

Hypericin + Placebo

Phase 3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CTCL/ Mycosis Fungoides

Conditions

CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma

Trial Timeline

Jan 7, 2025 → Oct 1, 2026

NCT ID
NCT06470451

About Hypericin + Placebo

Hypericin + Placebo is a phase 3 stage product being developed by Soligenix for CTCL/ Mycosis Fungoides. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06470451. Target conditions include CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides.

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06470451Phase 3Recruiting
NCT05442190Phase 2Completed